CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 118 enrolled
Drug / intervention
Implant of investigational device system +3 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01385176
NCT01385176N/AActive

Neural Cardiac Therapy for Heart Failure Study

Boston Scientific Corporation·interventional·Posted Jun 30, 2011·Updated Jun 30, 2026

In Brief

A clinical study evaluating Implant of investigational device system, Titration during the randomization phase, and 2 other interventions for Heart Failure and Congestive Heart Failure. Active but no longer recruiting, targeting 118 participants across 21 sites in 8 countries.

Detailed Summary

The NECTAR-HF feasibility trial is designed to evaluate the application of right vagal nerve stimulation in heart failure patients with a New York Heart Association Class III, an ejection fraction equal to or less than 35 %, and a narrow QRS duration equal to or less than 130 ms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Czechia, France, Germany, Italy, Netherlands, Spain, United Kingdom
Collaborators--

Timeline

N/AActiveOverdue
201220132014201520162017201820192020202120222023202420252026
First PostedJun 30, 2011
Enrollment StartSep 21, 2011
Primary CompletionMay 1, 2014
Study CompletionJun 30, 2026
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 15.0 years ago

Interventions

Implant of investigational device systemdevice

Vagus nerve stimulation lead was wrapped around the right cervical vagus nerve and then connected to a stimulator permanently implanted in the right pectoral region.

Titration during the randomization phaseprocedure

Amplitude of the chronically delivered vagus nerve stimulation in the experimental arm was adjusted to the highest tolerable by patient value. No chronically delivered vagus nerve stimulation in the control arm during the randomization phase.

Titration after the randomization phaseprocedure

Amplitude of the chronically delivered vagus nerve stimulation was adjusted to the highest tolerable by patient value in all patients in both arms of the study.

Blood Drawother

Blood draw before implant and 6 months after implant at the end of the randomization phase.